Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients
Gopal, Ajay K., Tarantolo, Stefano R., Bellam, Naresh, Green, Damian J., Griffin, Melissa, Feldman, Tatyana, Mato, Anthony R., Eisenfeld, Amy J., Stromatt, Scott C., Goy, AndreVolume:
32
Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-014-0125-2
Date:
December, 2014
File:
PDF, 528 KB
english, 2014